158 related articles for article (PubMed ID: 22897696)
1. Alloimmune platelet transfusion refractoriness circumvented by allogeneic stem cell transplantation.
Bonstein L; Stemer G; Dann EJ; Zuckerman T; Fineman R; Haddad N
Transfusion; 2013 May; 53(5):1019-23. PubMed ID: 22897696
[TBL] [Abstract][Full Text] [Related]
2. Bleeding risk and platelet transfusion refractoriness in patients with acute myelogenous leukemia who undergo autologous stem cell transplantation.
Toor AA; Choo SY; Little JA
Bone Marrow Transplant; 2000 Aug; 26(3):315-20. PubMed ID: 10967572
[TBL] [Abstract][Full Text] [Related]
3. [Emergence of donor-derived anti-HLA antibody and subsequent transfusion-refractory thrombocytopenia after allogeneic hematopoietic stem cell transplantation from an HLA-matched sibling donor in a patient with acute myeloid leukemia].
Uchiyama Y; Hoshino T; Mihara M; Mitsui T; Koiso H; Takizawa M; Yokohama A; Saitoh T; Uchiumi H; Handa H; Tsukamoto N; Murakami H; Nojima Y
Rinsho Ketsueki; 2013 Feb; 54(2):214-8. PubMed ID: 23470830
[TBL] [Abstract][Full Text] [Related]
4. Transfusion strategies in patients undergoing stem-cell transplantation.
Radia R; Pamphilon D
Expert Rev Hematol; 2011 Apr; 4(2):213-20. PubMed ID: 21495930
[TBL] [Abstract][Full Text] [Related]
5. Pretransplant platelet transfusion refractoriness is not associated with platelet nonengraftment in T-replete hematopoietic progenitor cell transplantation for hematologic malignancies.
Scott A; Baidya S; Butler J; Morris K; Thornton A; Kennedy GA
Transfusion; 2016 Jan; 56(1):164-9. PubMed ID: 26264674
[TBL] [Abstract][Full Text] [Related]
6. The mean fluorescence intensities of anti-HLA antibodies detected using micro-bead flow cytometry predict the risk of platelet transfusion refractoriness.
Beligaswatte A; Tsiopelas E; Humphreys I; Bennett G; Robinson K; Davis K; Bardy P
Br J Haematol; 2013 Aug; 162(3):409-12. PubMed ID: 23651440
[TBL] [Abstract][Full Text] [Related]
7. Platelet transfusion refractoriness due to graft-derived anti-HPA-2b production after allogeneic bone-marrow transplantation.
Taaning E; Jacobsen N
Transplant Proc; 1994 Jun; 26(3):1826. PubMed ID: 8030157
[No Abstract] [Full Text] [Related]
8. A possible role for the production of multiple HLA antibodies in fatal platelet transfusion refractoriness after peripheral blood progenitor cell transplantation from the mother in a patient with relapsed leukemia.
Nakazawa Y; Saito S; Hasegawa Y; Yanagisawa R; Sakashita K; Kamijo T; Miyazaki T; Sato S; Ikeda H; Ikebuchi K; Koike K
Transfusion; 2007 Feb; 47(2):326-34. PubMed ID: 17302780
[TBL] [Abstract][Full Text] [Related]
9. Human platelet antigen systems in allogeneic peripheral blood progenitor cell transplantation: effect of human platelet antigen mismatch on platelet engraftment and graft-versus-host disease.
García-Malo MD; Corral J; González M; Solano C; González-Conejero R; Caballero MD; Pérez R; Moraleda JM; Vicente V
Transfusion; 2004 May; 44(5):771-6. PubMed ID: 15104661
[TBL] [Abstract][Full Text] [Related]
10. Recipient-derived HPA-1a antibodies: a cause of prolonged thrombocytopenia after unrelated donor stem cell transplantation.
Lucas G; Culliford S; Green F; Sidra G; Calvert A; Green A; Harrison P; Harvey J; Allen D; Smillie D; Masurekar A; Marks D; Russell N; Massey E
Transfusion; 2010 Feb; 50(2):334-9. PubMed ID: 19874563
[TBL] [Abstract][Full Text] [Related]
11. Human Leukocyte Antigen Class I Antibodies and Response to Platelet Transfusion in Patients Undergoing Liver Transplantation.
Wong M; Narra R; Selim M; Zimmerman MA; Kim J; Padmanabhan A; Hong JC
J Surg Res; 2020 Nov; 255():99-105. PubMed ID: 32543385
[TBL] [Abstract][Full Text] [Related]
12. Platelet refractoriness due to combined anti-HLA and anti-HPA-5a alloantibodies: clinical management during myeloablative allogeneic HSCT and development of a quantitative MAIPA assay.
Arber C; Bertrand G; Halter J; Boehlen F; Kaplan C; Gratwohl A
Br J Haematol; 2007 Oct; 139(1):159-61. PubMed ID: 17854320
[No Abstract] [Full Text] [Related]
13. How we treat: risk mitigation for ABO-incompatible plasma in plateletpheresis products.
Fontaine MJ; Mills AM; Weiss S; Hong WJ; Viele M; Goodnough LT
Transfusion; 2012 Oct; 52(10):2081-5. PubMed ID: 22414003
[No Abstract] [Full Text] [Related]
14. Platelet refractoriness and alloimmunization in pediatric oncology and bone marrow transplant patients.
Hogge DE; McConnell M; Jacobson C; Sutherland HJ; Benny WB; Massing BG
Transfusion; 1995 Aug; 35(8):645-52. PubMed ID: 7631404
[TBL] [Abstract][Full Text] [Related]
15. Strategies for managing refractoriness to platelet transfusions.
Dan ME; Schiffer CA
Curr Hematol Rep; 2003 Mar; 2(2):158-64. PubMed ID: 12901147
[TBL] [Abstract][Full Text] [Related]
16. The investigation of platelet transfusion refractory in 69 malignant patients undergoing hematopoietic stem cell transplantation.
Li G; Liu F; Mao X; Hu L
Transfus Apher Sci; 2011 Aug; 45(1):21-4. PubMed ID: 21798807
[TBL] [Abstract][Full Text] [Related]
17. [Platelet transfusion refractoriness and effective management of platelet alloimmunization].
Amemiya Y
Nihon Rinsho; 1997 Sep; 55(9):2392-8. PubMed ID: 9301306
[TBL] [Abstract][Full Text] [Related]
18. Treatment of severe thrombocytopenia in alloimmunized, transfusion-refractory patients.
Ornstein DL; Mortara KL; Smith MB; Ririe DW; Shaughnessy PJ; Bickford DJ; Kissack BL
Mil Med; 2001 Mar; 166(3):269-74. PubMed ID: 11263033
[TBL] [Abstract][Full Text] [Related]
19. [Platelet alloimmunization in patients with oncologic blood disorders treated with multiple transfusions: prospective study in adults and children].
Pereira J; Bronfman L; Bertín P; Marzouka E; Hidalgo P; Amaya S; Mezzano D
Rev Med Chil; 1997 Nov; 125(11):1305-12. PubMed ID: 9609051
[TBL] [Abstract][Full Text] [Related]
20. Recent developments in the supportive therapy of acute myelogenous leukemia.
Levine AS; Deisseroth AB
Cancer; 1978 Aug; 42(2 Suppl):883-94. PubMed ID: 28827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
